Format

Send to

Choose Destination
See comment in PubMed Commons below
PLoS One. 2013 Nov 4;8(11):e79137. doi: 10.1371/journal.pone.0079137. eCollection 2013.

C-Met as a prognostic marker in gastric cancer: a systematic review and meta-analysis.

Author information

1
Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China.

Abstract

BACKGROUND:

c-Met has been recognized as an important therapeutic target in gastric cancer, but the prognostic property of the c-Met status is still unclear. We aimed to characterize the prognostic effect of c-Met by systematic review and meta-analysis.

METHODS:

We identified 15 studies assessing survival in gastric cancer by c-Met status. Effect measure of interest was hazard ratio (HR) for survival. Meta-regression was performed to estimate the relationship between HR and disease stage. Random-effects meta-analyses were used to account for heterogeneity.

RESULTS:

15 eligible studies provided outcome data stratified by c-Met status in 2210 patients. Meta-analysis of the HRs indicated a significantly poorer Os in patients with high c-Met expression (average HR=2.112, 95%CI: 1.622-2.748). Subgroup analysis showed the prognostic effect of c-Met was identical in protein-level and gene-level based methodology. The same effect was also seen in Asian and Western ethnicity subgroup analysis. Meta-regression showed HR was not associated with disease stage.

CONCLUSIONS:

Patients with tumors that harbor high c-Met expression are more likely to have a worse Os, with this prognostic effect independent of disease stage. c-Met status should be evaluated in clinical prognosis.

PMID:
24223894
PMCID:
PMC3817069
DOI:
10.1371/journal.pone.0079137
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Public Library of Science Icon for PubMed Central
    Loading ...
    Support Center